Amarin Corp Plc (AMRN)

[faxedreceipts]

The key takeaway here is that investors shouldn't sweat this capital raise. Amarin has proven to be a winning play for biopharma investors and this capital raise only creates more avenues for value creation in the years to come. Lastly, there's no reason to believe that a capital raise has any bearing on possible buyout talks -- other than the fact that Amarin would now be negotiating from a position of strength.

https://www.nasdaq.com/article/amarin-is-a-buyout-really-off-the-table-cm1179844